Qu, X., Hamidi, H., Johnson, R. M., Sokol, E. S., Lin, E., Eng, C., . . . Bais, C. Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer. Nature Portfolio.
Chicago Style (17th ed.) CitationQu, Xueping, et al. Ligand-activated EGFR/MAPK Signaling but Not PI3K, Are Key Resistance Mechanisms to EGFR-therapy in Colorectal Cancer. Nature Portfolio.
MLA (9th ed.) CitationQu, Xueping, et al. Ligand-activated EGFR/MAPK Signaling but Not PI3K, Are Key Resistance Mechanisms to EGFR-therapy in Colorectal Cancer. Nature Portfolio.
Warning: These citations may not always be 100% accurate.